Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Tysabri Court Loss Gets Elan Into Another Fine Mess

  • News

Executive Summary

On July 21, Elan CEO Kelly Martin kicked off his company's half-year earnings call with lots of good news, something rare for the Irish biotech in the past few years

You may also be interested in...



Elan Moves Ahead With J&J Deal, But Does Biogen Really Approve?

Is it over? Elan Corp. and Johnson & Johnson said Sept. 17 they successfully closed their deal to share Alzheimer disease programs

Elan Moves Ahead With J&J Deal, But Does Biogen Really Approve?

Is it over? Elan Corp. and Johnson & Johnson said Sept. 17 they successfully closed their deal to share Alzheimer disease programs

Judge Says Elan's J&J Deal Violates Tysabri Contract, Handing Biogen A Victory

Biogen Idec's lawyers took heat all day Thursday from a federal judge, but in the end she ruled in their favor. Now, Elan has 23 days to fix the breach.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

‘Decentralized Clinical Trials 2.0’ On The Horizon

Who Will Join Us? EU Regulators Seek Feedback On Proposed Clinical Trials Discussion Platform

Japan Changes Rules On Drug Names, Study Codes In Sponsors' Trial Sites

Teva Quits PhRMA As Financial, Policy Challenges Loom For The Brand/Generic Hybrid Giant

See All
UsernamePublicRestriction

Register

PS051466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By